NCT05079373

Brief Summary

The objective of this study is to support the exploration of the NEURO-COVID-19 database and in particular to carry out the post-treatments necessary to derive quantitative information on the characterization of the lesion load, in particular with regard to of the vascular tree

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
250

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Apr 2021

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

April 1, 2021

Completed
7 months until next milestone

First Submitted

Initial submission to the registry

October 13, 2021

Completed
2 days until next milestone

First Posted

Study publicly available on registry

October 15, 2021

Completed
12 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 9, 2022

Completed
22 days until next milestone

Study Completion

Last participant's last visit for all outcomes

October 31, 2022

Completed
Last Updated

November 30, 2021

Status Verified

October 1, 2021

Enrollment Period

1.5 years

First QC Date

October 13, 2021

Last Update Submit

November 17, 2021

Conditions

COVID-19

Keywords

COVID-19SARS-COV-2Central nervous systemHeadacheLoss of smellComa

Outcome Measures

Primary Outcomes (1)

  • Retrospective study of the neurological damage in patients with Covid-19

    Files analysed retrospectively from January 01, 2020 to October 31, 2021 will be examined]

Eligibility Criteria

Age18 Years+
Sexall
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Adult patient having covid and presenting with neurological symptoms leading to an MRI.

You may qualify if:

  • Adult patient (≥18 years old)
  • COVID + patient presenting with neurological symptoms leading to an MRI.
  • Patient taken care of in one of the care centers associated with this research
  • Patient not having expressed his opposition, after information, to the reuse of his data for the purposes of this research.

You may not qualify if:

  • Patient who expressed his opposition to participating in the study
  • COVID patient not having neurological symptoms or not having received an MRI
  • Patient under guardianship or guardianship
  • Patient under legal protection

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Service d'Imagerie 2 - Neuroradiologie et Radiologie Ostéo-articulaire - Hôpitaux Universitaires de Strasbourg

Strasbourg, 67091, France

RECRUITING

MeSH Terms

Conditions

COVID-19HeadacheAnosmiaComa

Condition Hierarchy (Ancestors)

Pneumonia, ViralPneumoniaRespiratory Tract InfectionsInfectionsVirus DiseasesCoronavirus InfectionsCoronaviridae InfectionsNidovirales InfectionsRNA Virus InfectionsLung DiseasesRespiratory Tract DiseasesPainNeurologic ManifestationsSigns and SymptomsPathological Conditions, Signs and SymptomsOlfaction DisordersSensation DisordersNervous System DiseasesUnconsciousnessConsciousness DisordersNeurobehavioral Manifestations

Central Study Contacts

Stephane Kremer, MD, PhD

CONTACT

33 3 88 12 78 89stephane.kremer@chru-strasbourg.fr

Saïd CHAYER, PhD, HDR

CONTACT

said.chayer@chru-strasbourg.fr

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

October 13, 2021

First Posted

October 15, 2021

Study Start

April 1, 2021

Primary Completion

October 9, 2022

Study Completion

October 31, 2022

Last Updated

November 30, 2021

Record last verified: 2021-10

Locations

FR(1)